Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av AZD0486 Plus Rituximab hos tidligere ubehandlede follikulært lymfompasienter

20. oktober 2026 oppdatert av: AstraZeneca

En fase III, multisenter, randomisert, åpen studie for å sammenligne effektiviteten og sikkerheten til AZD0486 Plus Rituximab versus Kjemoterapi Plus Rituximab hos tidligere ubehandlede deltakere med follikulært lymfom

This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.

Studieoversikt

Detaljert beskrivelse

The study consists of 2 sequential parts.

  1. Safety Run-in - this part will compare dose levels of Surovatamig (AZD0486) in combination with rituximab in order to establish the RP3D.

  2. Phase III - The Phase III part will assess the superiority of Surovatamig (AZD0486) at RP3D in combination with rituximab, compared to Investigator's choice between 3 standard chemoimmunotherapy regimens. Phase 3 consists of 3 arms

    1. Arm A: treatment with Surovatamig plus rituximab Schedule A
    2. Arm B: treatment with Surovatamig plus rituximab Schedule B
    3. Arm C (Comparator arm): one of the following standard regimens per Investigator's choice: R-CVP + rituximab maintenance, R-CHOP + rituximab maintenance or B-R + rituximab maintenance

Studietype

Intervensjonell

Registrering (Antatt)

1018

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Clayton, Australia, 3168
        • Har ikke rekruttert ennå
        • Research Site
      • Darlinghurst, Australia, 2010
        • Rekruttering
        • Research Site
      • Garran, Australia, 2605
        • Rekruttering
        • Research Site
      • Heidelberg, Australia, 3084
        • Rekruttering
        • Research Site
      • Macquarie University, Australia, 2109
        • Rekruttering
        • Research Site
      • Nedlands, Australia, 6009
        • Rekruttering
        • Research Site
      • Brussels, Belgia, 1070
        • Har ikke rekruttert ennå
        • Research Site
      • Brussels, Belgia, 1090
        • Har ikke rekruttert ennå
        • Research Site
      • Ghent, Belgia, 9000
        • Har ikke rekruttert ennå
        • Research Site
      • Mechelen, Belgia, 2800
        • Har ikke rekruttert ennå
        • Research Site
      • Porto Alegre, Brasil, 90035-003
        • Rekruttering
        • Research Site
      • São Paulo, Brasil, 04501-000
        • Rekruttering
        • Research Site
      • São Paulo, Brasil, 05652-900
        • Rekruttering
        • Research Site
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • Rekruttering
        • Research Site
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
        • Rekruttering
        • Research Site
    • Ontario
      • Barrie, Ontario, Canada, L4M 6M2
        • Tilbaketrukket
        • Research Site
      • Hamilton, Ontario, Canada, L8V 5C2
        • Rekruttering
        • Research Site
      • Oshawa, Ontario, Canada, L1G 2B9
        • Rekruttering
        • Research Site
      • Toronto, Ontario, Canada, M5G 1X6
        • Rekruttering
        • Research Site
    • Quebec
      • Chicoutimi, Quebec, Canada, G7H 5H6
        • Rekruttering
        • Research Site
      • Montreal, Quebec, Canada, H4J 1C5
        • Rekruttering
        • Research Site
      • Québec, Quebec, Canada, G1J 1Z4
        • Rekruttering
        • Research Site
      • Saint-Jérôme, Quebec, Canada, J7Z 2V4
        • Rekruttering
        • Research Site
      • Aalborg, Danmark, 9100
        • Tilbaketrukket
        • Research Site
      • Copenhagen, Danmark, 2100
        • Rekruttering
        • Research Site
      • Odense C, Danmark, 5000
        • Rekruttering
        • Research Site
      • Roskilde, Danmark, 4000
        • Tilbaketrukket
        • Research Site
      • Helsinki, Finland, 00029
        • Tilbaketrukket
        • Research Site
      • Kuopio, Finland, 70029
        • Tilbaketrukket
        • Research Site
      • Tampere, Finland, 33520
        • Tilbaketrukket
        • Research Site
    • Alabama
      • Huntsville, Alabama, Forente stater, 35805
        • Rekruttering
        • Research Site
    • Alaska
      • Anchorage, Alaska, Forente stater, 99508
        • Rekruttering
        • Research Site
    • Arizona
      • Phoenix, Arizona, Forente stater, 85054
        • Rekruttering
        • Research Site
    • California
      • Clovis, California, Forente stater, 93611
        • Har ikke rekruttert ennå
        • Research Site
      • Los Alamitos, California, Forente stater, 90720
        • Rekruttering
        • Research Site
      • San Diego, California, Forente stater, 92121
        • Har ikke rekruttert ennå
        • Research Site
      • Santa Monica, California, Forente stater, 90404
        • Har ikke rekruttert ennå
        • Research Site
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Tilbaketrukket
        • Research Site
    • Connecticut
      • New Haven, Connecticut, Forente stater, 06510
        • Rekruttering
        • Research Site
    • Delaware
      • Newark, Delaware, Forente stater, 19713
        • Har ikke rekruttert ennå
        • Research Site
    • Florida
      • Jacksonville, Florida, Forente stater, 32224
        • Rekruttering
        • Research Site
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Har ikke rekruttert ennå
        • Research Site
      • Macon, Georgia, Forente stater, 31201
        • Rekruttering
        • Research Site
    • Illinois
      • Evanston, Illinois, Forente stater, 60201
        • Har ikke rekruttert ennå
        • Research Site
      • Peoria, Illinois, Forente stater, 61615
        • Har ikke rekruttert ennå
        • Research Site
    • Indiana
      • Fort Wayne, Indiana, Forente stater, 46804
        • Rekruttering
        • Research Site
    • Iowa
      • Des Moines, Iowa, Forente stater, 50309
        • Har ikke rekruttert ennå
        • Research Site
      • Iowa City, Iowa, Forente stater, 52242
        • Har ikke rekruttert ennå
        • Research Site
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40536
        • Har ikke rekruttert ennå
        • Research Site
      • Louisville, Kentucky, Forente stater, 40207
        • Har ikke rekruttert ennå
        • Research Site
    • Louisiana
      • Baton Rouge, Louisiana, Forente stater, 70808
        • Har ikke rekruttert ennå
        • Research Site
    • Maryland
      • Baltimore, Maryland, Forente stater, 21201
        • Har ikke rekruttert ennå
        • Research Site
      • Bethesda, Maryland, Forente stater, 20817
        • Rekruttering
        • Research Site
      • Columbia, Maryland, Forente stater, 21044
        • Har ikke rekruttert ennå
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Har ikke rekruttert ennå
        • Research Site
      • Boston, Massachusetts, Forente stater, 02215
        • Har ikke rekruttert ennå
        • Research Site
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • Har ikke rekruttert ennå
        • Research Site
      • Detroit, Michigan, Forente stater, 48201
        • Tilbaketrukket
        • Research Site
      • Ypsilanti, Michigan, Forente stater, 48197
        • Har ikke rekruttert ennå
        • Research Site
    • Minnesota
      • Rochester, Minnesota, Forente stater, 55905
        • Rekruttering
        • Research Site
      • Saint Paul, Minnesota, Forente stater, 55102
        • Har ikke rekruttert ennå
        • Research Site
    • Missouri
      • Chesterfield, Missouri, Forente stater, 63017
        • Har ikke rekruttert ennå
        • Research Site
      • Springfield, Missouri, Forente stater, 65807
        • Rekruttering
        • Research Site
    • New Jersey
      • Hackensack, New Jersey, Forente stater, 07601
        • Har ikke rekruttert ennå
        • Research Site
      • New Brunswick, New Jersey, Forente stater, 08901
        • Har ikke rekruttert ennå
        • Research Site
    • New York
      • Albany, New York, Forente stater, 12206
        • Rekruttering
        • Research Site
      • Brooklyn, New York, Forente stater, 11220
        • Har ikke rekruttert ennå
        • Research Site
      • Mineola, New York, Forente stater, 11501
        • Har ikke rekruttert ennå
        • Research Site
      • New Hyde Park, New York, Forente stater, 11042
        • Har ikke rekruttert ennå
        • Research Site
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Research Site
      • New York, New York, Forente stater, 10032
        • Rekruttering
        • Research Site
      • New York, New York, Forente stater, 10016
        • Rekruttering
        • Research Site
    • North Carolina
      • Charlotte, North Carolina, Forente stater, 28204
        • Rekruttering
        • Research Site
      • Charlotte, North Carolina, Forente stater, 28204
        • Har ikke rekruttert ennå
        • Research Site
      • Wilmington, North Carolina, Forente stater, 28401
        • Har ikke rekruttert ennå
        • Research Site
      • Winston-Salem, North Carolina, Forente stater, 27103
        • Har ikke rekruttert ennå
        • Research Site
    • Ohio
      • Blue Ash, Ohio, Forente stater, 45242
        • Har ikke rekruttert ennå
        • Research Site
      • Cincinnati, Ohio, Forente stater, 45219
        • Har ikke rekruttert ennå
        • Research Site
      • Columbus, Ohio, Forente stater, 43210
        • Har ikke rekruttert ennå
        • Research Site
    • Oregon
      • Eugene, Oregon, Forente stater, 97401
        • Har ikke rekruttert ennå
        • Research Site
      • Portland, Oregon, Forente stater, 97227
        • Tilbaketrukket
        • Research Site
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • Har ikke rekruttert ennå
        • Research Site
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Rekruttering
        • Research Site
    • Texas
      • Austin, Texas, Forente stater, 78705
        • Har ikke rekruttert ennå
        • Research Site
      • Lubbock, Texas, Forente stater, 79430
        • Har ikke rekruttert ennå
        • Research Site
      • Shenandoah, Texas, Forente stater, 77380
        • Har ikke rekruttert ennå
        • Research Site
      • Tyler, Texas, Forente stater, 75702
        • Har ikke rekruttert ennå
        • Research Site
    • Utah
      • Salt Lake City, Utah, Forente stater, 84112
        • Har ikke rekruttert ennå
        • Research Site
    • Virginia
      • Fairfax, Virginia, Forente stater, 22031
        • Har ikke rekruttert ennå
        • Research Site
      • Richmond, Virginia, Forente stater, 23219
        • Har ikke rekruttert ennå
        • Research Site
    • Washington
      • Tacoma, Washington, Forente stater, 98405
        • Rekruttering
        • Research Site
    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53792
        • Har ikke rekruttert ennå
        • Research Site
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Har ikke rekruttert ennå
        • Research Site
      • Bayonne, Frankrike, 64100
        • Har ikke rekruttert ennå
        • Research Site
      • La Tronche, Frankrike, 38700
        • Tilbaketrukket
        • Research Site
      • Lille, Frankrike, 59037
        • Har ikke rekruttert ennå
        • Research Site
      • Montpellier, Frankrike, 34295
        • Har ikke rekruttert ennå
        • Research Site
      • Saint-Cloud, Frankrike, 92210
        • Har ikke rekruttert ennå
        • Research Site
      • Vandœuvre-lès-Nancy, Frankrike, 54511
        • Tilbaketrukket
        • Research Site
      • Hong Kong, Hong Kong, 999077
        • Rekruttering
        • Research Site
      • Delhi, India, 110029
        • Har ikke rekruttert ennå
        • Research Site
      • Delhi, India, 110085
        • Rekruttering
        • Research Site
      • Gurugram, India, 122002
        • Har ikke rekruttert ennå
        • Research Site
      • Kolkata, India, 700160
        • Rekruttering
        • Research Site
      • Nashik, India, 422002
        • Rekruttering
        • Research Site
      • Surat, India, 396007
        • Rekruttering
        • Research Site
      • Thiruvananthapuram, India, 695011
        • Rekruttering
        • Research Site
      • Bologna, Italia, 40138
        • Har ikke rekruttert ennå
        • Research Site
      • Milan, Italia, 20141
        • Har ikke rekruttert ennå
        • Research Site
      • Reggio Emilia, Italia, 42100
        • Har ikke rekruttert ennå
        • Research Site
      • Bunkyō City, Japan, 113-8677
        • Rekruttering
        • Research Site
      • Chiba, Japan, 260-8717
        • Rekruttering
        • Research Site
      • Chuo-shi, Japan, 409-3898
        • Rekruttering
        • Research Site
      • Fukuoka, Japan, 812-8582
        • Rekruttering
        • Research Site
      • Hirakata-shi, Japan, 573-1191
        • Rekruttering
        • Research Site
      • Kobe, Japan, 650-0047
        • Rekruttering
        • Research Site
      • Kumamoto, Japan, 860-8556
        • Rekruttering
        • Research Site
      • Kurashiki-shi, Japan, 710-8602
        • Rekruttering
        • Research Site
      • Kyoto, Japan, 602-8566
        • Rekruttering
        • Research Site
      • Kōtoku, Japan, 135-8550
        • Rekruttering
        • Research Site
      • Minatoku, Japan, 105-8470
        • Rekruttering
        • Research Site
      • Okayama, Japan, 700-8558
        • Rekruttering
        • Research Site
      • Osaka, Japan, 541-8567
        • Rekruttering
        • Research Site
      • Sapporo, Japan, 060-8638
        • Rekruttering
        • Research Site
      • Sapporo, Japan, 003-0006
        • Rekruttering
        • Research Site
      • Sunto-gun, Japan, 411-8777
        • Rekruttering
        • Research Site
      • Toyoake-shi, Japan, 470-1192
        • Rekruttering
        • Research Site
      • Yamagata, Japan, 990-9585
        • Rekruttering
        • Research Site
      • Yokohama, Japan, 241-8515
        • Rekruttering
        • Research Site
      • Beijing, Kina, 100730
        • Rekruttering
        • Research Site
      • Beijing, Kina, 100044
        • Rekruttering
        • Research Site
      • Beijing, Kina, 100142
        • Rekruttering
        • Research Site
      • Changchun, Kina, 130021
        • Rekruttering
        • Research Site
      • Changsha, Kina, 410013
        • Rekruttering
        • Research Site
      • Chengdu, Kina, 610078
        • Rekruttering
        • Research Site
      • Chongqing, Kina, 400030
        • Rekruttering
        • Research Site
      • Fuzhou, Kina, 350001
        • Rekruttering
        • Research Site
      • Guangzhou, Kina, 510060
        • Rekruttering
        • Research Site
      • Guangzhou, Kina, 510100
        • Rekruttering
        • Research Site
      • Guangzhou, Kina, 510000
        • Rekruttering
        • Research Site
      • Hangzhou, Kina, 310022
        • Har ikke rekruttert ennå
        • Research Site
      • Hangzhou, Kina, 310003
        • Rekruttering
        • Research Site
      • Harbin, Kina, 150081
        • Rekruttering
        • Research Site
      • Hefei, Kina, 230031
        • Rekruttering
        • Research Site
      • Lanzhou, Kina, 730000
        • Rekruttering
        • Research Site
      • Nanchang, Kina, 330006
        • Rekruttering
        • Research Site
      • Nanchang, Kina, 330029
        • Rekruttering
        • Research Site
      • Nanjing, Kina, 210029
        • Rekruttering
        • Research Site
      • Nanning, Kina, 530021
        • Rekruttering
        • Research Site
      • Shandong, Kina, 250117
        • Rekruttering
        • Research Site
      • Shanghai, Kina, 200065
        • Rekruttering
        • Research Site
      • Shanghai, Kina, 20032
        • Rekruttering
        • Research Site
      • Shenyang, Kina, 110001
        • Rekruttering
        • Research Site
      • Shenyang, Kina, 110004
        • Rekruttering
        • Research Site
      • Shijiazhuang, Kina, 054001
        • Rekruttering
        • Research Site
      • Suzhou, Kina, 215006
        • Rekruttering
        • Research Site
      • Tianjin, Kina, 300020
        • Rekruttering
        • Research Site
      • Wenzhou, Kina, 325000
        • Rekruttering
        • Research Site
      • Wuhan, Kina, 430079
        • Rekruttering
        • Research Site
      • Xi'an, Kina, 710114
        • Rekruttering
        • Research Site
      • Xiamen, Kina, 361003
        • Rekruttering
        • Research Site
      • Zhengzhou, Kina, 450000
        • Rekruttering
        • Research Site
      • Zhengzhou, Kina, 450008
        • Rekruttering
        • Research Site
      • Gdansk, Polen, 80-214
        • Har ikke rekruttert ennå
        • Research Site
      • Gliwice, Polen, 44-102
        • Tilbaketrukket
        • Research Site
      • Katowice, Polen, 40-519
        • Har ikke rekruttert ennå
        • Research Site
      • Krakow, Polen, 30-727
        • Har ikke rekruttert ennå
        • Research Site
      • Lublin, Polen, 20-081
        • Tilbaketrukket
        • Research Site
      • Lublin, Polen, 20-090
        • Suspendert
        • Research Site
      • Warsaw, Polen, 02-781
        • Har ikke rekruttert ennå
        • Research Site
      • Wroclaw, Polen, 50-019
        • Har ikke rekruttert ennå
        • Research Site
      • Wroclaw, Polen, 53-439
        • Tilbaketrukket
        • Research Site
      • San Juan, Puerto Rico, 00918
        • Rekruttering
        • Research Site
      • Barcelona, Spania, 08035
        • Har ikke rekruttert ennå
        • Research Site
      • Barcelona, Spania, 8036
        • Tilbaketrukket
        • Research Site
      • El Palmar, Spania, 30120
        • Tilbaketrukket
        • Research Site
      • Girona, Spania, 17007
        • Har ikke rekruttert ennå
        • Research Site
      • Las Palmas de Gran Canaria, Spania, 35020
        • Tilbaketrukket
        • Research Site
      • Madrid, Spania, 28041
        • Har ikke rekruttert ennå
        • Research Site
      • Madrid, Spania, 28040
        • Tilbaketrukket
        • Research Site
      • Oviedo, Spania, 33011
        • Tilbaketrukket
        • Research Site
      • Pamplona, Spania, 31008
        • Tilbaketrukket
        • Research Site
      • Santander, Spania, 39008
        • Har ikke rekruttert ennå
        • Research Site
      • London, Storbritannia, SE5 9RS
        • Rekruttering
        • Research Site
      • London, Storbritannia, EC1M6BQ
        • Rekruttering
        • Research Site
      • Newcastle upon Tyne, Storbritannia, NE7 7DN
        • Rekruttering
        • Research Site
      • Norwich, Storbritannia, NR4 7UY
        • Rekruttering
        • Research Site
      • Nottingham, Storbritannia, NG5 1PB
        • Rekruttering
        • Research Site
      • Plymouth, Storbritannia, PL6 8DH
        • Rekruttering
        • Research Site
      • Southampton, Storbritannia, SO16 6YD
        • Tilbaketrukket
        • Research Site
      • Falun, Sverige, 79182
        • Tilbaketrukket
        • Research Site
      • Uppsala, Sverige, 75185
        • Tilbaketrukket
        • Research Site
      • Busan, Sør -Korea, 49201
        • Rekruttering
        • Research Site
      • Busan, Sør -Korea, 49241
        • Rekruttering
        • Research Site
      • Goyang-si, Sør -Korea, 10408
        • Rekruttering
        • Research Site
      • Jeonnam, Sør -Korea, 519-763
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 03080
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 06351
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 05505
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 03722
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 06591
        • Rekruttering
        • Research Site
      • Changhua, Taiwan, 50006
        • Rekruttering
        • Research Site
      • Kaohsiung City, Taiwan, 80756
        • Rekruttering
        • Research Site
      • Kaohsiung City, Taiwan, 833
        • Rekruttering
        • Research Site
      • Lukang Township, Taiwan, 505029
        • Rekruttering
        • Research Site
      • Tainan, Taiwan, 704
        • Rekruttering
        • Research Site
      • Taipei, Taiwan, 106
        • Rekruttering
        • Research Site
      • Bangkok, Thailand, 10330
        • Rekruttering
        • Research Site
      • Bangkok, Thailand, 10700
        • Rekruttering
        • Research Site
      • Chiang Mai, Thailand, 50200
        • Rekruttering
        • Research Site
      • Khon Kaen, Thailand, 40002
        • Rekruttering
        • Research Site
      • Brno, Tsjekkia, 625 00
        • Har ikke rekruttert ennå
        • Research Site
      • Hradec Králové, Tsjekkia, 500 05
        • Har ikke rekruttert ennå
        • Research Site
      • Prague, Tsjekkia, 12808
        • Har ikke rekruttert ennå
        • Research Site
      • Ankara, Tyrkia (Türkiye), 6200
        • Har ikke rekruttert ennå
        • Research Site
      • Ankara, Tyrkia (Türkiye), 6620
        • Har ikke rekruttert ennå
        • Research Site
      • Istanbul, Tyrkia (Türkiye), 34890
        • Har ikke rekruttert ennå
        • Research Site
      • Istanbul, Tyrkia (Türkiye), 34010
        • Har ikke rekruttert ennå
        • Research Site
      • Izmir, Tyrkia (Türkiye), 35340
        • Tilbaketrukket
        • Research Site
      • Berlin, Tyskland, 10967
        • Har ikke rekruttert ennå
        • Research Site
      • Berlin, Tyskland, 13353
        • Har ikke rekruttert ennå
        • Research Site
      • Deggendorf, Tyskland, 94469
        • Har ikke rekruttert ennå
        • Research Site
      • Düsseldorf, Tyskland, 40479
        • Har ikke rekruttert ennå
        • Research Site
      • Göttingen, Tyskland, 37075
        • Har ikke rekruttert ennå
        • Research Site
      • Hamburg, Tyskland, 20246
        • Har ikke rekruttert ennå
        • Research Site
      • Heidelberg, Tyskland, 69120
        • Har ikke rekruttert ennå
        • Research Site
      • Jena, Tyskland, 07747
        • Har ikke rekruttert ennå
        • Research Site
      • Karlsruhe, Tyskland, 76133
        • Har ikke rekruttert ennå
        • Research Site
      • Kiel, Tyskland, 24105
        • Har ikke rekruttert ennå
        • Research Site
      • Lübeck, Tyskland, 23538
        • Har ikke rekruttert ennå
        • Research Site
      • Magdeburg, Tyskland, 39120
        • Har ikke rekruttert ennå
        • Research Site
      • Minden, Tyskland, 32429
        • Har ikke rekruttert ennå
        • Research Site
      • München, Tyskland, 81377, DE
        • Har ikke rekruttert ennå
        • Research Site
      • Münster, Tyskland, 48129
        • Har ikke rekruttert ennå
        • Research Site
      • Regensburgs, Tyskland, 93049
        • Har ikke rekruttert ennå
        • Research Site
      • Würzburg, Tyskland, 97080
        • Har ikke rekruttert ennå
        • Research Site
      • Budapest, Ungarn, 1122
        • Tilbaketrukket
        • Research Site
      • Budapest, Ungarn, 1088
        • Tilbaketrukket
        • Research Site
      • Debrecen, Ungarn, 4032
        • Har ikke rekruttert ennå
        • Research Site
      • Győr, Ungarn, 9024
        • Har ikke rekruttert ennå
        • Research Site
      • Kaposvár, Ungarn, 7400
        • Har ikke rekruttert ennå
        • Research Site
      • Nyíregyháza, Ungarn, 4400
        • Tilbaketrukket
        • Research Site
      • Pécs, Ungarn, 7624
        • Har ikke rekruttert ennå
        • Research Site
      • Szeged, Ungarn, 6725
        • Har ikke rekruttert ennå
        • Research Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 130 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Participant must be at least 18 years of age, inclusive, at the time of signing the ICF.
  2. Histologically confirmed diagnosis of classic FL per WHO 2022 classification
  3. ECOG performance status of 0 to 2
  4. No prior systemic lymphoma-directed therapy
  5. Need for systemic treatment meeting at least 1 GELF criteria
  6. FDG-avid and measurable disease
  7. Stage II to IV and FLIPI 2-5 [Phase III only]
  8. Adequate liver, hematological, renal and cardiac function.

The above is a summary, other inclusion criteria details may apply

Exclusion Criteria:

  1. Follicular large B-cell lymphoma (WHO 2022 classification), formerly Follicular lymphoma Grade 3B (WHO 2016 classification) or suspicion for histologic transformation to high-grade/aggressive lymphoma
  2. Contra-indication to BR, RCVP, and R-CHOP
  3. Participants with or history of CNS lymphoma
  4. History of a clinically relevant CNS medical condition or pathology that required treatment in the preceding year, is currently symptomatic or that which the treating investigator considers to have the potential to interfere with the evaluation of safety
  5. Presence of >5000 circulating lymphoma cells
  6. Active or uncontrolled infection (including EBV) requiring systemic therapy and which places participant at unacceptable risk if he/she were to participate in the study. If a participant has a history of COVID-19 within 1 month of C1D1 or contracts COVID while on study treatment, participant must have 2 consecutive negative tests (PCR testing is preferable) performed at least 48 hours apart prior to resuming dosing. All symptoms related to COVID-19 infection should have fully resolved before initiating or resuming treatment
  7. Known history of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)

The above is a summary, other exclusion criteria details may apply

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Rituximab, Surovatamig - A

Surovatamig regimen A plus rituximab

a fully human bispecific monoclonal IgG4 antibody

Andre navn:
  • AZD0486
Eksperimentell: Rituximab, Surovatamig - B

Surovatamig regimen B plus rituximab

a fully human bispecific monoclonal IgG4 antibody

Andre navn:
  • AZD0486
Aktiv komparator: Chemoimmunotherapy

Investigator's choice between 3 standard immunochemotherapy regimen (R-CHOP, R-CVP, or B-R followed by rituximab maintenance)

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone

Rituximab, Cyclophosphamide, Vincristine and Prednisone

Bendamustine, Rituximab

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEs
Tidsramme: Up to 10 years

Frequency, severity, and relationship to study drug of AEs and SAEs; dose modifications; changes in physical examination and safety procedures.

Up to 10 years
SRI Primary: Determination of the recommended Phase III dose (RP3D)
Tidsramme: Up to 1 year

The RP3D will be the dose of Surovatamig selected for the Phase 3 part based on safety data compiled during the safety run-in part

Up to 1 year
Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
Tidsramme: Up to 10 years

PFS, based on Lugano 2014 Response Criteria, as assessed by BICR.

Up to 10 years
Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
Tidsramme: Up to 10 years

ORR at EoI, based on Lugano 2014 Response Criteria, as assessed by BICR.

Up to 10 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety Run in and Phase 3: ORR at EoI (Investigator assessed)
Tidsramme: Up to 10 years

ORR defined as the proportion of participants achieving either a PR or CR at End of Induction based on Lugano 2014 Response Criteria

Up to 10 years
Safety Run In and Phase 3: CR Rate
Tidsramme: Up to 10 years

CR rate is defined as the proportion of participants achieving a CR at any time as based on Lugano 2014 Response Criteria

Up to 10 years
Safety Run In and Phase 3: CR at EoI
Tidsramme: Up to 10 years

Proportion of participants achieving CR at End of Induction based on Lugano 2014 Response Criteria

Up to 10 years
Safety Run In and Phase 3: DoR
Tidsramme: up to 10 years

DoR will be defined from the time of first response until progression based on Lugano 2014 criteria, or death due to any cause

up to 10 years
Safety Run In and Phase 3: PFS (Investigator assessed)
Tidsramme: Up to 10 years

PFS (Investigator assessed) is defined as time from randomization until disease progression based on Lugano 2014 Response Criteria or death due to any cause

Up to 10 years
Safety Run In and Phase 3: OS
Tidsramme: Up to 10 years

OS is defined as time until the date of death

Up to 10 years
Phase 3: CR rate at 30 months (CR30)
Tidsramme: Up to 30 months

Proportion of participants in CR rate at 30 months (CR30) based on Lugano 2014 Response Criteria

Up to 30 months
Phase 3: Time to First Subsequent Therapy or Death (TFST)
Tidsramme: Up to 10 Years

TFST will be defined as the time from randomization until the start date of first subsequent anti-lymphoma therapy or death due to any cause

Up to 10 Years
Phase 3: Time from randomisation to second progression or death (PFS2)
Tidsramme: Up to 10 Years

PFS2 will be defined as the time from randomization until the earliest of the progression event, after first subsequent therapy, or death due to any cause

Up to 10 Years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Chan Cheah, MBBS FRACP FRCPA DMSc, Sir Charles Gairdner Hospital (SCGH)

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. august 2024

Primær fullføring (Antatt)

26. november 2031

Studiet fullført (Antatt)

26. november 2031

Datoer for studieregistrering

Først innsendt

29. juli 2024

Først innsendt som oppfylte QC-kriteriene

7. august 2024

Først lagt ut (Faktiske)

12. august 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

21. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • D7401C00001
  • 2023 (U.S. NIH-stipend/kontrakt)
  • 2023-510098-33-00 (Registeridentifikator: CTIS (EU))

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Tilgangskriterier for IPD-deling

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere